Dosing study for older adults with advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies how well different doses of CDK4/6 inhibitors (palbociclib or ribociclib) work in people aged 65 or older with HR+/HER2- metastatic breast cancer. It aims to find the best starting dose to balance effectiveness and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years or older.
- You must have advanced breast cancer that is hormone receptor positive and HER2 negative.
- You should be starting your first CDK4/6 inhibitor (palbociclib or ribociclib) along with hormone therapy (like letrozole, anastrozole, exemestane, or fulvestrant).
- Your blood counts and liver/kidney function must be within acceptable ranges.
- You cannot have taken a CDK4/6 inhibitor before for metastatic breast cancer, or in the last 12 months for early breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests if a higher dose of palbociclib together with hydroxychloroquine and hormone therapy works better than the standard dose of palbociclib with hormone therapy. It is for people with hormone receptor-positive, HER2-negative breast cancer that has spread and has not been treated yet.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.